Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Walking remains most popular activity despite low guideline adherence

1

Apr 2026

Walking remains most popular activity despite low guideline adherence

In a study of U.S. adults, walking was, by far, the most popular leisure-time physical activity, while rural residents also enjoyed gardening, hunting and fishing, and urban residents more commonly reported running, weightlifting and dance. Urban residents were more likely than rural residents to meet physical activity guidelines.

AEGIS tool helps scientists study evolution of aging and lifespan

1

Apr 2026

AEGIS tool helps scientists study evolution of aging and lifespan

Why do some species live for only weeks while others survive for centuries? Researchers at the Leibniz Institute on Aging - Fritz Lipmann Institute (FLI) in Jena have developed AEGIS, a freely available software tool that enables scientists to simulate evolution on a standard computer and investigate how lifespan and aging evolve under different ecological pressures and genetic constraints.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.